NOTION: TAVI with low risk at 4 year follow up

Courtesy of the SBHCI.

NOTION: TAVI with Low Risk at 4 Year Follow UpThere is little data about the use of transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis at low surgical risk. Many of the questions involve long term duration of valves (over 10 years) when treating younger patients with longer life expectancy.

 

The NOTION study aims at comparing TAVR (with the self-expandable CoreValve) vs. conventional valve replacement surgery in patients over 70 years old at low surgical risk. This article reports on its 4 year outcomes.

 

The NOTION (Nordic Aortic Valve Intervention) randomized 280 patients between 2009 and 2013 with a mean STS of around 3 (more than 80% had <4 STS).

 

Primary end point was a composite of death, infarction or stroke according to VARC II criteria, that resulted 30.2% at 4 year follow up for patients undergoing surgery vs. 29.1% for the TAVR group (p=0.76).

 

Global mortality was 23% for surgery vs. 20% for the TAVR group (p=0.56). Also the rate of stroke resulted similar (surgery 7.3% vs. TAVR 6.8%), as well as that of infarction.

 

When looking only at patients between 70 and 75 (all with STS ≤4), primary end point was 27.2% for surgery and 15.6% for TAVR (p=0.24).

 

The differences between methods were seen in atrial fibrillation, that was far more frequent in the surgery group (60.2% vs 24.5%; p<0.001), and in the need for pacemaker, far more frequent with TAVR (9% vs. 43.7%, p<0,001).

 

Conclusion

Patients with severe aortic stenosis at low risk randomized to surgery vs. transcatheter aortic valve replacement showed similar results at 4 years as regards primary end point.

 

Differences were seen basically in new atrial fibrillation rate, which favored TAVR and in the need of pacemaker, which favored surgery. 

 

Courtesy of SBHCI

 

Dr. Lars Sondergaard
Dr. Lars Sondergaard.

Original Title: Clinical, safety and echocardiographic outcomes from NOTION trial: 4-year follow-up data in all-comer patients with severe aortic valve stenosis.

Presenter: Lars Sondergaard.

 

 

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...